Tyk2 Inhibitor

Tyk2 Inhibitors (69):

Cat. No.	Product Name	Effect	Purity

HY-13961

GLPG0634 analog	Inhibitor	98.07%
GLPG0634 analog (Compoun 176) is a broad spectrum JAK inhibitor with IC₅₀ values of <100 nM against JAK1, JAK2 and JAK3.

HY-150720

TYK2-IN-12	Inhibitor	98.81%
TYK2-IN-12 (compound 30) is an orally active, potent and selective TYK2 (tyrosine kinase 2) inhibitor, with a K_i of 0.51 nM. TYK2-IN-12 inhibits IL-12 induced IFNγ, with IC₅₀ values of 2.7 and 7.0 μM in human and mouse whole blood, respectively. TYK2-IN-12 can be used for psoriasis research.

HY-152080

TUL01101	Inhibitor	99.71%
TUL01101 is a potent, selective and orally active JAK1 inhibitor, with an IC₅₀s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. TUL01101 can be used for the research of rheumatoid arthritis.

HY-18710

BMS-066	Inhibitor	99.09%
BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC₅₀s of 9 nM and 72 nM, respectively.

HY-153440

JAK-IN-25	Inhibitor	98.44%
JAK-IN-25 (compound 19) is a potent JAK inhibitor with IC₅₀s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC₅₀ of 28 nM. JAK-IN-25 has the potential for cancer research.

HY-148060

JAK-IN-21	Inhibitor	99.72%
JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC₅₀s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively.

HY-50859

Ruxolitinib sulfate	Inhibitor
Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC₅₀s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.

HY-18315

Bayer-18	Inhibitor
Bayer-18 is an inhibitor for TYK2. Bayer-18 inhibits the viability of ALCL cell K299, SR786, Mac1 and Mac2a with IC₅₀ of 2-3 µM, and induces apoptosis in K299 and SR786.

HY-19569A

Upadacitinib tartrate tetrahydrate	Inhibitor
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research.

HY-19568A

Peficitinib hydrobromide	Inhibitor
Peficitinib (ASP015K) hydrobromide is an orally active JAK inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

HY-14722C

NVP-BSK805 trihydrochloride	Inhibitor
NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.

HY-16379A

Pacritinib hydrochloride	Inhibitor
Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC₅₀=23 nM) and JAK2^V617F mutant (IC₅₀=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3^D835Y (IC₅₀=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF).

HY-153058

LRRK2-IN-8	Inhibitor
LRRK2-IN-8 is a LRRK2 inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC₅₀s lower than 10 nM, and inhibits TYK2 and NUAK1 with IC₅₀s of 10-100 nM.

HY-18709

Tyk2-IN-3	Inhibitor
Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC₅₀ of 485 nM.

HY-163304

Tyk2-IN-16	Inhibitor
Tyk2-IN-16 is a selective and potent TYK2 inhibitor with an IC₅₀ of <10 nM for TYK2-JH2. Tyk2-IN-16 inhibits pSTAT4 with an IC₅₀ of <10 nM in NK92 cells (WO2023220046A1; compound 184).

HY-19568B

Peficitinib hydrochloride	Inhibitor
Peficitinib (ASP015K) hydrochloride is an orally active JAK inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

HY-154994

JAK-IN-30	Inhibitor
JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC₅₀ values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED).

HY-143885

JAK1/TYK2-IN-3	Inhibitor
JAK1/TYK2-IN-3 is a potent, selective and orally active dual TYK2/JAK1 inhibitor with IC₅₀ values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to JAK2 (IC₅₀=140 nM) and JAK3 (IC₅₀=362 nM). JAK1/TYK2-IN-3 shows anti-inflammatory effect by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells.

HY-153103

LRRK2/NUAK1/TYK2-IN-1	Inhibitor
LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), TYK2 and NUAK1, with IC₅₀ values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research.

HY-149296

JAK1-IN-12	Inhibitor
JAK1-IN-12 is a selective inhibitor of JAK1, with IC₅₀ of 0.0246 μM. And IC₅₀s of 0.423 μM, 0.410 μM and 1.12 μM for JAK2, JAK3 and TYK2. JAK1-IN-12 promotes hair growth in mice. JAK1-IN-12 can be used for research of immune and inflammatory diseases.

Name
Email *

	Sorry, but the email address you supplied was invalid.